Abstract:IMPORTANCE Anlotinib is a novel multitarget tyrosine kinase inhibitor for tumor angiogenesis and proliferative signaling. A phase 2 trial showed anlotinib to improve progression-free survival with a potential benefit of overall survival, leading to the phase 3 trial to confirm the drug's efficacy in advanced non-small cell lung cancer (NSCLC). OBJECTIVE To investigate the efficacy of anlotinib on overall survival of patients with advanced NSCLC progressing after second-line or further treatment. DESIGN, SETTING, AND PARTICIPANTS The ALTER 0303 trial was a multicenter, double-blind, phase 3 randomized clinical trial designed to evaluate the efficacy and safety of anlotinib in patients with advanced NSCLC. Patients from 31 grade-A tertiary hospitals in China were enrolled between March 1, 2015, and August 31, 2016. Those aged 18 to 75 years who had histologically or cytologically confirmed NSCLC were eligible (n = 606), and those who had centrally located squamous cell carcinoma with cavitary features or brain metastases that were uncontrolled or controlled for less than 2 months were excluded. Patients (n = 440) were randomly assigned in a 2-to-1 ratio to receive either 12 mg/d of anlotinib or a matched placebo. All cases were treated with study drugs at least once in accordance with the intention-to-treat principle. MAIN OUTCOMES AND MEASURES The primary end point was overall survival. The secondary end points were progression-free survival, objective response rate, disease control rate, quality of life, and safety. RESULTS In total, 439 patients were randomized, 296 to the anlotinib group (106 [36.1%] were female and 188 [64.0%] were male, with a mean [SD] age of 57.9 [9.1] years) and 143 to the placebo group (46 [32.2%] were female and 97 [67.8%] were male, with a mean [SD] age of 56.8 [9.1] years). Overall survival was significantly longer in the anlotinib group (median, 9.6 months; 95% CI, 8.2-10.6) than the placebo group (median, 6.3 months; 95% CI, 5.0-8.1), with a hazard ratio (HR) of 0.68 (95% CI, 0.54-0.87; P =.002). A substantial increase in progression-free survival was noted in the anlotinib group compared with the placebo group (median, 5.4 months [95% CI, 4.4-5.6] vs 1.4 months [95% CI, 1.1-1.5]; HR, 0.25 [95% CI, 0.19-0.31]; P <.001). Considerable improvement in objective response rate and disease control rate was observed in the anlotinib group over the placebo group. The most common grade 3 or higher adverse events in the anlotinib arm were hypertension and hyponatremia. CONCLUSIONS AND RELEVANCE Among the Chinese patients in this trial, anlotinib appears to lead to prolonged overall survival and progression-free survival. This finding suggests that anlotinib is well tolerated and is a potential third-line or further therapy for patients with advanced NSCLC.

Subgroup Analysis of Elderly Patients (pts) in ALTER0303: Anlotinib Hydrochloride As 3Rd-Line and Further Line Treatment in Refractory Advanced NSCLC Pts from a Randomized, Double-Blind, Placebo-Controlled Phase III ALTER0303 Trial.

Third-line Treatment: A Randomized, Double-Blind, Placebo-Controlled Phase III ALTER-0303 Study—efficacy and Safety of Anlotinib Treatment in Patients with Refractory Advanced NSCLC.

Subgroup Analysis of Histology in ALTER0303: Anlotinib Hydrochloride As 3rd Line and Further Line Treatment in Refractory Advanced NSCLC Patients (Pts).

P2.03a-001 A Randomized Phase III Clinical Trial of Anlotinib Hydrochloride in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)

Efficiency Of Anlotinib Hydrochloride As 3rd Line Treatment In Patients (Pts) From A Randomized, Double-Blind, Placebo-Controlled Phase Iii Trial, An Exploratory Subgroup Analysis Of Alter0303 Trial For The Previous Therapy Strategy Effect

1336P Anlotinib in Elderly Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Who Had Not Received Systemic Chemotherapy: A Single-Arm, Multi-Center, Phase II Study

EP08.02-033 Anlotinib in Elderly Patients with Advanced Non-squamous NSCLC Who Had Not Received Systemic Chemotherapy: A Single-Arm, Phase II Study

Dose Modification and Therapy Interruption Due to Adverse Events in Treatment with Anlotinib for Refractory Advanced NSCLC: Data from ALTER0303

Anlotinib Monotherapy for Refractory Metastatic Colorectal Cancer: A Double-Blinded, Placebo-Controlled, Randomized Phase III Trial (ALTER0703)

Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial.

Efficacy and Safety of Third-Line Treatment with Anlotinib in Patients with Refractory Advanced Non-Small-Cell Lung Cancer (Alter-0303): A Randomised, Double-Blind, Placebo-Controlled Phase 3 Study

P3.03-006 Efficiency of Anlotinib As 3rd Line Treatment in Patients with Different EGFR Gene Status, an Exploratory Subgroup Analysis of ALTER0303 Trial

Effect of Anlotinib As a Third‐ or Further‐line Therapy in Advanced Non‐small Cell Lung Cancer Patients with Different Histologic Types: Subgroup Analysis in the ALTER0303 Trial

P1.01-107 the Impact of Anlotinib on Quality of Life in Patients with Advance NSCLC: Post-Hoc Analysis of a Phase III Randomized Control Trial (ALTER0303)

Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302)

Effect of Anlotinib As a Third-Line or Further Treatment on Overall Survival of Patients with Advanced Non–Small Cell Lung Cancer

P3.01-087 Impact Factor Analysis for Efficacy and Prognosis of Anlotinib in NSCLC As Third-Line Treatment: Data from Trial ALTER 0303

Quality of Life Results from a Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Phase III Trial of Anlotinib in Patients with Advanced Non-Small Cell Lung Cancer

Clinical Outcomes of Patients with or Without Common AEs in Anlotinib Cohort: Subgroup Analysis of the ALTER0303 Trial.

The impact of previous therapy strategy on the efficiency of anlotinib hydrochloride as a third-line treatment on patients with advanced non-small cell lung cancer (NSCLC): a subgroup analysis of ALTER0303 trial

The Efficacy Of Anlotinib In Squamous Cell Carcinoma (Scc) Patients With Or Without Hypertension In Alter0303: Anlotinib As A Third-Line Therapy In Patients With Advanced Non-Small Cell Lung Cancer (Nsclc).